疏肝消脂Ⅲ方胶囊对非酒精性脂肪性肝病大鼠肝组织过氧化物酶体增殖物激活受体γ及脂联素受体2表达的影响
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases(2016)
Abstract
目的:探讨疏肝消脂Ⅲ方胶囊对非酒精性脂肪肝性肝病(NAFLD)大鼠的防治作用及对肝组织过氧化物酶体增殖物激活受体γ(PPAR-γ)和脂联素受体2(Adipo R2) mRNA表达的影响.方法:将46只大鼠分为4组,除正常组(10只)外,其余3组大鼠(各12只)均用高脂乳剂灌胃建立NAFLD模型,于灌胃第6周末形成脂肪肝后,分别给消脂方和水飞蓟组大鼠灌胃疏肝消脂Ⅲ方胶囊和水飞蓟宾胶囊4周,检测大鼠血糖(FBG);应用酶联免疫法(Elisa)法检测胰岛素(FINS)含量并计算胰岛素抵抗指数(HO-MA-IR);荧光定量(qPCR)法测定大鼠肝组织PPAR-γ、Adipo R2的mRNA表达.结果:①两药物组大鼠FBG、FINS和HOMA-IR水平较模型组降低(P<0.05);②消脂Ⅲ方组大鼠PPAR-γ、Adipo R2的mRNA水平较模型组升高(P<0.05).结论:疏肝消脂Ⅲ方胶囊能改善NAFLD大鼠胰岛素抵抗,保护肝脏,作用机制可能与PPAR-γ、Adipo R2表达有关.
MoreKey words
Shugan xiaozhi Ⅲ capsule,Non-alcoholic fatty liver,Peroxisome proliferator-activated receptor γ,Adiponectin receptor 2
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined